Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):37-51

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):37-51

NEUROENDOCRINE UPDATE AND METABOLIC THERAPY 

    REVIEWS

Dosimetry for treatment with radiolabelled somatostatin analogues. A review

Cremonesi M. 1, Botta F. 1, Di Dia A. 1, Ferrari M. 1, Bodei L. 2, De Cicco C. 2, Rossi A. 1, Bartolomei M. 3, Mei R. 2, Severi S. 4, Salvatori M. 5, Pedroli G. 1, Paganelli G. 2

1 Medical Physics, European Institute of Oncology, Milan, Italy;
2 Nuclear Medicine Divisions, European Institute of Oncology, Milan, Italy;
3 Nuclear Medicine Institute, Ospedale Bufalini, Cesena, Italy;
4 Division of Nuclear Medicine, Scientific Institute for the study and treatment of tumors, Meldola, Italy;
5 Institute for Nuclear Medicine, S. Cuore Catholic University, Rome, Italy

Peptide Receptor Radionuclide Therapy (PRRT) has proven its efficacy in the treatment of neuroendocrine and other somatostatin receptor expressing tumours (SR-tumours). Several clinical trials have confirmed that adverse effects are represented by possible renal impairment, which is the major concern, and low but not absent hematological toxicity. High kidney irradiation is a constant, despite the sparing of dose obtained by renal protectors. Hematological toxicity, although low, needs to be monitored. The clinical and dosimetry results collected in more than a decade have recognized weak points to unravel, increased knowledge, offering new views. When planning therapy with radiopeptides, the large patients’ variability as for biodistribution and tumour uptake must be taken into account in order to tailor the therapy, or at least to avoid foreseeable gross treatments. Reliable and personalized dosimetry is more and more requested. This paper reviews through the literature the methods to study the biokinetics, the dosimetry outcomes, some clue information and correlations obtained once applying the radiobiological models. Special focus is given on recent improvements and indications for critical organ protection that light up challenging perspectives for PRRT.

language: English


FULL TEXT  REPRINTS

top of page